Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines - Protagonist Therapeutics ( NASDAQ:PTGX )
Truist Securities initiated coverage on Protagonist Therapeutics Inc PTGX, citing its first-in-class lead asset with encouraging Phase 2 data in a rare form of blood cancer and a multi-billion dollar opportunity.
| Ticker |
Sentiment |
Impact |
|
PTGX
|
Bullish
|
47 %
|
|
JNJ
|
Bullish
|
63 %
|
|
TAK
|
Bullish
|
20 %
|
